Sheel Biotech IPO Details
The key details of Sheel Biotech’s IPO are outlined below, covering all crucial aspects from price range to investment requirements and regulatory documents.
| IPO Size | ₹34.02 Cr |
| Price Range | ₹59 - ₹63 |
| Retail Quota | 35% |
| QIB Quota | 50% |
| NII Quota | 15% |
| Employee Discount | -- |
| Listing at | NSE |
| Minimum Quantity | 4,000 |
| Investment (cut-off price) | ₹2,52,000 |
| Pre IPO Promotor Holding | 96.99% |
| Post IPO Promotor Holding | 71.26% |
| DHRP Draft | Click Here |
| RHP Draft | Click Here |
| Anchor Investors List | Click Here |
Sheel Biotech IPO Timelines
The IPO process for Sheel Biotech includes key dates for participants to know. The timeline allows for strategic planning and participation, helping investors stay informed and engaged throughout the entire process.
30/09/2025
Start Date03/10/2025
End Date07/10/2025
Refund Initiation07/10/2025
Credit of Shares to Demat Ac08/10/2025
Listing DateSheel Biotech IPO Lot Size
The Sheel Biotech IPO has a fixed lot size of 2,000 shares, at an upper price band of ₹63 per share. For retail investors, the minimum and maximum application is 4,000 shares (2 lots) amounting to ₹2,52,000. For Small HNI (S-HNI) investors, the minimum application is 6,000 shares (3 lots) worth ₹3,78,000, while the maximum is 14,000 shares (7 lots) amounting to ₹8,82,000. Big HNI (B-HNI) investors need to apply for at least 16,000 shares (8 lots), totaling ₹10,08,000.
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 2 | 4000 | ₹2,52,000 |
| Retail Maximum | 2 | 4000 | ₹2,52,000 |
| S-HNI Minimum | 3 | 6000 | ₹3,78,000 |
| S-HNI Maximum | 7 | 14000 | ₹8,82,000 |
| B-HNI Minimum | 8 | 16000 | ₹10,08,000 |
Sheel Biotech IPO Subscription Status
The subscription status for Sheel Biotech IPO shows market demand across different investor categories, providing valuable insights into the offering’s performance. You can track real-time subscription data below.
| QIB | NII | Retail | EMP | Total |
|---|---|---|---|---|
| 19.73x | 25.92x | 9.56x | -- | 15.97x |
IPO Performance on Listing Day
On the listing day (October 08, 2025), Sheel Biotech made an impressive debut on the stock exchange. The stock opened at ₹91, commanding a strong premium of 44.4% over its issue price of ₹63. The biotechnology company gained further momentum throughout the trading session, reaching a day high of ₹95.55, while finding solid support at the opening price level. The shares concluded their first trading day at ₹95.55, which also marked the day’s high, delivering an exceptional gain of 51.7% over the issue price, reflecting extraordinary investor confidence in the biotechnology sector and strong market enthusiasm for this life sciences solutions provider.
| Opening Price | Closing Price | Day High | Day Low |
|---|---|---|---|
| ₹91.00 | ₹95.55 | ₹95.55 | ₹91.00 |
Sheel Biotech IPO Company Financials
Sheel Biotech reports robust performance in FY2025 with Total Income of ₹102.27 crores, managing expenses at ₹89.45 crores, and achieving a strong PAT (Profit After Tax) of ₹10.64 crores, demonstrating significant growth potential ahead of its public offering.
| Year | Total Income | Total Expense | PAT |
|---|---|---|---|
| FY 2023 | ₹80.19 | ₹73.82 | ₹5.08 |
| FY 2024 | ₹92.55 | ₹80.29 | ₹10.47 |
| FY 2025 | ₹102.27 | ₹89.45 | ₹10.64 |
About Company
Sheel Biotech Limited, incorporated in November 1991, is engaged in biotechnology, floriculture, greenhouse solutions, and organic agriculture projects. The company produces and supplies a wide range of planting materials for field crops, fruits, vegetables, and ornamental plants using advanced tissue culture and hydroponic techniques. It also designs and constructs modern greenhouses and turnkey horticultural projects, integrating technologies such as climate control, automation, drip irrigation, and fertigation to improve crop quality and yield. In addition, Sheel Biotech provides landscaping services to both government and private clients.
The company holds certifications including ISO 9001:2015, ISO 14001:2015, and ISO 45001:2018, reflecting its commitment to quality, environmental sustainability, and occupational safety. Its Research and Development laboratory is recognized by the Department of Biotechnology and the Department of Science and Technology of the Government of India. Sheel Biotech supports farmers through services like organic adoption and certification, Farmer Producer Organization management, and skill development initiatives. These include training programs, workshops, and exposure visits to promote modern agricultural practices. As of September 12, 2025, the company employs 160 permanent staff members.
| Incorporation Date | Sector | Managing Director |
|---|---|---|
| 1991 | Agricultural | Divye Chandak |
Know Before Investing
Sheel Biotech IPO Strengths
- Sheel Biotech Limited, incorporated in 1991, has over three decades of experience in biotechnology, floriculture, greenhouses, and organic farming projects, making it a seasoned player in the agricultural biotech sector.
- The company operates across multiple segments including plant tissue culture, organic adoption and certification, greenhouses, horticulture projects, and turnkey agricultural solutions, providing a broad revenue base.
- Sheel Biotech boasts one of the largest tissue culture laboratories in northern India with an annual plant production capacity of over 20 million plants, supporting high-volume supply capabilities.
- The company’s R&D labs are recognized by the Department of Biotechnology and Department of Science and Technology, underpinning innovation and quality improvements.
- Sheel Biotech manages organic adoption and certification programs over 45,000 hectares involving over 30,000 farmers, positioning it as a key promoter of sustainable and organic agriculture.
- With expertise in turnkey horticulture projects and greenhouse setups, the company provides end-to-end solutions that enhance productivity and client satisfaction.
Sheel Biotech IPO Risks
- Being tied closely to agriculture and related sectors, the company’s performance can be impacted by factors like monsoon variability, soil health, and crop cycles.
- Compliance with organic certification standards and government regulations involves complex procedures, with risks of certification delays or revocations.
- Tissue culture and greenhouse operations require precise technical execution; any process failures can impact product quality and yields.
- Faces competition from other tissue culture labs, organic certifiers, and agricultural solution providers, affecting pricing and market share.
- A significant portion of revenue may stem from a limited number of institutional clients or geographic regions, increasing vulnerability to their contract renewals or demand shifts.
- Dependence on specialized raw materials, equipment, and skilled personnel may lead to operational disruptions.
Swot Analysis for Sheel Biotech IPO
Strengths
Extensive Geographic Presence, Diverse Product and Service Portfolio, Sustainability and Organic Focus
Weaknesses
Dependency on Agricultural Sector, Regional Market Concentration, Slow Adoption of New Tech
Opportunities
Rising Organic Farming Demand, Technological Advancements, Sustainability-Linked Funding
Threats
Climate Change Risks, Market Competition, Supply Chain Disruptions
Company Details
Sheel Biotech Ltd.
8 Balaji Estates, 2nd Floor, Block-C, Guru Ravidas Marg, Kalkaji, South Delhi, New Delhi, India, 110019
Phone: +91 88511 – 8980
Email: compliance@sheelbiotech.com
Website: http://www.sheelbiotech.com/
IPO Registar Details
Skyline Financial Services Pvt. Ltd.
Phone: 02228511022
Email: compliances@skylinerta.com
Website: https://www.skylinerta.com/ipo.php
FAQs
The key objectives of Sheel Biotech SME IPO are:
- Capital Expenditure Requirement
- Working Capital Requirement
- General Corporate Purposes
Narnolia Financial Services Ltd. is the book-running lead managers for the Sheel Biotech IPO.
Sheel Biotech IPO holds strong growth potential with revenue rising 15.41% to ₹92.55 crore in FY24 and profit more than doubling to ₹10.51 crore. Backed by ISO certifications, advanced R&D, and expanding demand for tissue culture and organic farming, prospects remain robust.
The issue price for the Sheel Biotech IPO is set between ₹59 to ₹63 per share.
To invest in one lot of Sheel Biotech IPO, you need ₹2,36,000 at the lower price band (₹59 per share) or ₹2,52,000 at the upper price band (₹63 per share) for a lot size of 4000 shares.
Sheel Biotech IPO shares are scheduled to be listed on the National Stock Exchange (NSE) on October 8, 2025.
Refund/unblocking of funds for Sheel Biotech IPO will begin on October 7, 2025. ASBA/UPI blocks will be removed within 1 working day.
You can sell shares your Sheel Biotech IPO shares on listing day (October 8, 2025) after they are credited to your demat account. If you want to sell in the pre-open market, the timing for that session is from 9:00 AM to 9:15 AM. Otherwise, you can sell after 10:00 AM during regular trading hours.